LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

LLY

1,068.03

-1.36%↓

JNJ

223.26

-0.34%↓

ABBV

215.81

+1.3%↑

UNH

376.01

-0.62%↓

MRK

116.35

+1%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

32.42 -6.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

32.26

Max

34.15

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-5M -128M
Pardavimai	6.8M 11M
Pelnas, tenkantis vienai akcijai	-1.23
Pelno marža	-1,191.029
Darbuotojai	594
EBITDA	-18M -139M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+155.33% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-469M 3.9B
Ankstesnė atidarymo kaina	38.45
Ankstesnė uždarymo kaina	32.42

Naujienos nuotaikos

By Acuity

50%

153 / 344 reitingas Healthcare

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-01 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

2026-06-01 23:38; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

2026-06-01 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Dexus Stuck in 'Too Hard' Basket -- Market Talk

2026-06-01 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

2026-06-01 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Greg Abel's Week Is Off to Quite a Start -- WSJ

2026-06-01 21:53; UTC

Rinkos pokalbiai

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

2026-06-01 21:22; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-01 20:46; UTC

Įsigijimai, susijungimai, perėmimai

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

2026-06-01 20:22; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares $11 Special Div

2026-06-01 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

2026-06-01 19:40; UTC

Rinkos pokalbiai

Remittances to Mexico Rise for Third Straight Month -- Market Talk

2026-06-01 19:28; UTC

Rinkos pokalbiai

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

2026-06-01 19:01; UTC

Rinkos pokalbiai

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

2026-06-01 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

2026-06-01 18:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

2026-06-01 18:33; UTC

Rinkos pokalbiai

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

2026-06-01 18:32; UTC

Rinkos pokalbiai

Precious Metals Fall to Start June -- Market Talk

2026-06-01 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 17:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

155.33% į viršų

12 mėnesių prognozė

Vidutinis 88.14 USD 155.33%

Aukščiausias 97 USD

Žemiausias 81 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

153 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.